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Background: Obesity is now a worldwide epidemic disease and poses a major risk for diet related diseases like
type 2 diabetes, cardiovascular disease, stroke and fatty liver among others. In the present study we employed the
murine model of diet-induced obesity to determine the early, tissue-specific, gene expression signatures that characterized
progression to obesity and type 2 diabetes.
Results: We used the C57BL/6 J mouse which is known as a counterpart for diet-induced human diabetes and obesity
model. Our initial experiments involved two groups of mice, one on normal diet (ND) and the other on high-fat and
high-sucrose (HFHSD). The later were then further separated into subgroups that either received no additional treatment,
or were treated with different doses of the Ayurvedic formulation KAL-1. At different time points (week3, week6, week9,
week12, week15 and week18) eight different tissues were isolated from mice being fed on different diet compositions.
These tissues were used to extract gene-expression data through microarray experiment. Simultaneously, we also measured
different body parameters like body weight, blood Glucose level and cytokines profile (anti-inflammatory &
pro-inflammatory) at each time point for all the groups.
Using partial least square discriminant analysis (PLS-DA) method we identified gene-expression signatures that predict
physiological parameters like blood glucose levels, body weight and the balance of pro- versus anti-inflammatory cytokines.
The resulting models successfully predicted diet-induced changes in body weight and blood glucose levels, although the
predictive power for cytokines profiles was relatively poor. In the former two instances, however, we could exploit the
models to further extract the early gene-expression signatures that accurately predict the onset of diabetes and obesity.
These extracted genes allowed definition of the regulatory network involved in progression of disease.
Conclusion: We identified the early gene-expression signature for the onset of obesity and type 2 diabetes. Further analysis
of this data suggests that some of these genes could be used as potential biomarkers for these two disease-states.
Keywords: Obesity, Type-II diabetes, Gene signature, Partial least square model, Biological classifications, Hub-proteinsBackground
The World Health Organization (WHO) recently pub-
lished that there are over 500 million adults in the whole
world who were found to be clinically obese [1]. Obesity
is described as an accumulation of adipose tissue and
caused by a combination of environmental factors such* Correspondence: samrat.ct@gmail.com
†Equal contributors
1Immunology Group, International Centre for Genetic Engineering and
Biotechnology, Aruna, Asaf Ali Marg, New Delhi 110067, India
2Present address: Drug Discovery Research Centre, Translational Health
Science & Technology Institute, Gurgaon 122016, India
© 2014 Sinha et al.; licensee BioMed Central; l
terms of the Creative Commons Attribution L
use, distribution, and reproduction in any medas excessive dietary calorie intake, lack of physical activ-
ity and genetic susceptibility [2,3]. In spite obesity has
been recognized as a problem for decades, it is still on
the rise and gradually gaining an epidemic status swap-
ping malnutrition and infectious diseases [2]. Moreover,
obesity may cause other health problems, like develop-
ment of type 2 diabetes mellitus (T2D), coronary heart
disease, certain form of cancer etc. [4]. Among these
health problems, T2D showed a major link with obese pa-
tients and thus undoubtedly comes up as another intri-
guing health problem of 21st century. T2D is a syndromeicensee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly credited.
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hyperglycaemia, but also by dyslipidaemia i.e. elevated trigly-
ceride (TG), and elevated plasma free fatty acid (FFA) levels.
Although pharmaceutical approaches to track the
problem of obesity and its related disorders are being ag-
gressively pursued, approaches evaluating treatment with
alternative forms of herbal medicine are also of interest.
For instance, Shao et al. [5] showed that curcumin is ef-
fective in the treatment of obesity and diabetes. More re-
cently Tikoo et. al. [6] showed that KAL-1, a formulation
derived from Ayurveda which a system of Indian Trad-
itional Medicine, was extremely effective at suppressing
the development of diet-induced obesity in the mouse
model. Importantly, development of other related disor-
ders of type 2 diabetes and systemic inflammation was
also prevented.
Diet is one of the widespread environmental determi-
nants for the onset of obesity and T2D. Thus, to study
obesity and diabetes, we employed the diet-induced
mouse model where mice were fed on a “high calorie
diet” consisting of high-fat and high-sucrose (HFHSD).
Our initial experiments involved two groups of mice,
one on HFHSD and the other on normal diet (ND).
HFHSD fed mice were then further separated into sub-
groups that either received no additional treatment, or
were treated with different doses of the Ayurvedic for-
mulation KAL-1. Experimental results, based on the
physiological parameters like body weight, blood glucose
levels and cytokine profiles, confirmed the earlier find-
ings [6] that KAL-1 prevented mice from both obesity
and diabetes. Thus, by comparing between the different
groups, our experimental system offered an opportunity
to identify disease-specific perturbations in gene expres-
sion in different tissues. Further, it was also our intent to
employ this data for the subsequent extraction of gene
expression signatures that specified progression towards
diabetes and/or obesity.
So, a primary aim of the present study is to get a gene/
molecular signatures for obesity and diabetes by establish-
ing a relation between the early gene expressions and late
body response. These molecular signatures could be effi-
ciently used to evaluate relevant biological formulations in
a quick and very efficient rapid assay system based on gene
expression profiling.
To obtain the molecular signature we developed a
model using partial least square discriminant analysis
(PLS-DA) method [7]. This algorithm is useful when
multi-collinearity exists among explanatory variables and
when the number of explanatory variables is very large
compared to the number of observations. PLS-DA ana-
lysis reduces the multiple dimensions of data set to a prin-
cipal component space and regress independent and
dependent principal components. In our case, we used
this algorithm model to find the relationship between theearly gene-expression values (independent variable) and
late physiological responses like body weight, blood glu-
cose levels or cytokine profiles (dependent variable). We
succeeded in identifying a set of genes whose early expres-
sion pattern correlated with the subsequent development
of obesity and diabetes. A subsequent interrogation of the
resulting tissue-specific gene expression signatures then
helped to distinguish those genes, or groups of genes




All animal experiments were performed at BIONEEDS
(Laboratory animals & Preclinical services) Bangalore,
India, and approved by institutional animal ethics com-
mittee (IAEC). BIONEEDS is approved by committee for
the purpose of control and supervision of experiments
on animals (CPCSEA), Ministry of forests and environ-
ments, Government of India. In the present study, we
used the C57BL/6 J mouse which is known as a counter-
part for diet-induced human diabetes and obesity model
since this strain accumulates adipose tissue mass, insulin
resistance, hyper-insulinemia, and hyper-lipidemia which
is very similar to humans fed on an HFHSD [8-10]. The
mice were kept at 12:12 hr light: dark photoperiod with
ad libitum access to food and water. Weaned mice at the
age of 3-4 weeks were divided randomly into five
groups- (each group contains 30 animals): first group
was fed on ND with 10% of calories coming from fat,
the second group was HFHSD fed group with increased
sucrose and 60% of calories coming from fat (Research
diets Inc.USA), and the third, fourth and fifth group of
mice were fed on HFHSD with different doses of an
ethano-botanical formulation, KAL-1 and we named
them as KAL-5 (5 μg of KAL-1+ HFHSD), KAL-20
(20 μg of KAL-1+ HFHSD) and KAL-75 (75 μg of
KAL-1+ HFHSD). The daily weight of this aqueous for-
mulation was 700 mg/ml. A schematic diagram showing
the preparation of KAL-1 is given in Figure 1(a).
We generated vast data sets for gene-expression across
different tissues from mice being fed on different diet
compositions. Tissues were selected on the basis of their
anticipated role in obesity, diabetes, or inflammation.
The selected tissues were liver, skeletal muscle, brown
adipose tissue (BA), white adipose tissue from the epi-
didymal (EA) and subcutaneous (SA) regions, and puri-
fied infiltrating macrophages (SVCs) from each of these
adipose tissue sites [11-13].
The mice were periodically monitored over an eighteen
week period. At the interval of every 3 weeks, five animals
from each group were sacrificed and different tissues were
extracted and frozen in liquid nitrogen prior to RNA ex-
traction. The SVC macrophages and adipocytes tissues
Figure 1 KAL-1 formulation and its effect on body weight and blood glucose. (a) Procedure for preparation of KAL-1 kwath. Flow chart
showing the step-wise preparation of Ayurvedic formulation termed as KAL-1[6]. This formulation was given to the mice at different concentration
(5 μl, 20 μl and 75 μl) along with HFHSD. (b)– (d) Body weight and Blood glucose results. (b) The difference between the body weights of the HFHSD
mice and ND mice is given for each time point. (c) The difference between the blood glucose levels of the HFHSD mice and ND mice is given for each
time point. (d) The average body weight of different group of mice at week 15 and blood glucose of different group of mice at week 12 with respect
to the body parameter of ND mice is given.
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in brief, adipose tissue (BA, EA and SA regions) were iso-
lated, weighed and collagenase solution was added in the
concentration of 3 ml/g of the tissue. Further, tissues werehomogenized and the tissue solution was kept in shaking
water bath at 37°C for 45 minutes. After centrifugation at
3600 rpm for 26 minutes, the pellet was treated with
erythrocyte lysis buffer and adipocytes layer was saved for
Table 1 Table summarizing tissue-wise model result for different body parameters
Tissues Body weight model Blood glucose model Anti cytokine model Pro cytokine model
Adipose BA Model worked Model worked Model not worked Model worked
Adipose EA Model not worked Model not worked Model worked Model worked
Adipose SA Model worked Model worked Model worked Model worked
SVC BA Model worked Model worked Model not worked Model worked
SVC EA Model not worked Model worked Model worked Model worked
SVC SA Model not worked Model not worked Model not worked Model not worked
Skeletal Model worked Model worked Model worked Model worked
Liver Model not worked Model not worked Model worked Model worked
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3500 rpm/10 min and the resulting pellet was dissolved in
1x PBS, further, biotin binder beads were added and solu-
tion was collected as SVC macrophages. The adipocytes
layer obtained was further processed with collagenase and
incubated at 37°C for 30 minutes in shaking water bath.
After centrifugation at 3600 rpm for 20 min pellet was ob-
tained and was kept as adipocytes. The SVC macrophages
and adipocytes for all the three tissues were frozen and sent
for RNA extraction.
Isolated tissues were then used to extract gene-expression
data for different time points (week3, week6, week9, week12,
week15 and week18) for all tissues through microarray ex-
periment. Simultaneously, we also measured different body
parameters like body weight, blood Glucose level and cyto-
kines profile (anti-inflammatory & pro-inflammatory) at
each time point for all the groups, see Figure 1(b).
Normalization and noise filtration in micro-array data
The gene-expression data were normalized according
to Agilent protocols. Probe level data were sum-
marized into a single expression value for each gene
on each array using GCRMA in GeneSpring GX 11
(Agilent Technologies, http://www.chem.agilent.com/).
GeneSpring (http://genespring-support.com/files/gs_12_
6/GeneSpring-manual.pdf, page 919 and page 920)
take care for probable batch effect. Array normalization
involved non-linear background reduction, quantile nor-
malization, and summarization by median polishing [14].
Moreover, for each time point we normalize the test data
with the control data (ND) to take care of week-wise
variation.
In the normalized data we have probe name with Gene
Bank accession, gene symbol, name and description. Fur-
ther for each probe we have three replicate samples and
their respective geometric mean with p-value. The gene
expressions in the list were given in log2-scale ratio bet-
ween different groups with ND group. A gene is said to
be significantly regulated if its expression value is greater
than 1 (up-regulation) or less than −1 (down-regulation)
i.e., two folds up or down with respect to the control. Ifthe expression value lies between −1 and 1, then the
gene is said to be insignificantly perturbed. To remove
noise from the data and to maintain consistency we se-
lected only those genes which showed same kind of
regulation throughout all the three replicates. Further, in
this filtered gene list, we observed that there are some
genes present in more than one probe and have different
expression values. Therefore, as a final step of gene se-
lection, we select those genes from the duplicate probes
that have geometric mean with minimum p-value (2-
tailed T-test). This non-redundant (and noise free) set of
genes obtained for each time point (i.e., week3, week6,
week9, week12, week15 and week18) is called the master
list (see Additional file 1 where the master list for week
3 and week 6 is given for Skeletal and Adipose SA for
HFHSD, KAL-5, KAL-20 and KAL-75).
Model formulation
We followed modelling approach that is based on a multi-
variate statistical method called Partial least square discrim-
inant analysis (PLS-DA) [7]. We used SIMCA P+ from
Umetrics to do this analysis [15]. The main goal of the
PLS-DA model is to predict a set of dependent variable (Y)
from a set of independent variables (X). For the PLS-DA
model we first defined an independent and a dependent set
of variables.
When the models were run, each of them produced a par-
ticular R2 and Q2 value. R2 is the percent of variation of
the training set – X with PCA and Y with PLS – explained
by the model. R2 is a measure of fit, i.e. how well the model
fits the data [15]. A large R2 (close to 1) is a necessary con-
dition for a good model. Q2 is the percent of variation of
the training set – X with PCA and Y with PLS – predicted
by the model according to cross validation. Q2 indicates
how well the model predicts new data. A large Q2 (Q2 >
0.5) indicates good predictivity. Poor Q2 values were gener-
ally obtained either when the data are noisy, or if the rela-
tionship X→Y is poor, or when the model is dominated by
a few scattered outliers. In the trained model, the independ-
ent variables are ranked depending on a score called variable
importance in projection (VIP). The scores are obtained
Figure 2 The figure showing (left side) R2-Q2 value for body weight and blood glucose training model and (right side) observed vs.
predicted graph for the same model. (a) body weight model for skeletal tissue; (b) blood glucose model for skeletal tissue; (c) body weight
model for adipose tissue; (d) blood glucose model for adipose tissue.
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Figure 3 The figure showing R2-Q2 value for cytokines (anti-inflammatory and pro-inflammatory) training model. (a) anti-inflammatory
cytokine model for skeletal tissue; (b) pro-inflammatory cytokine model for skeletal tissue; (c) anti-inflammatory cytokine model for adipose SA tissue;
(d) pro-inflammatory cytokine model for adipose tissue.
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a measure for the predictive ability of the variable with
respect to a particular parameter (for details see Additional
file 2). Using a cut off value for the VIP score (Additional
file 2) we select the top ranked variables and then again built
our model with those selected variables.Results
Extraction of the molecular signature for obesity and
diabetes
In PLS-DA model, we took gene-expression values as the
set of independent variables and dependent variable were
the physiological parameters like body weight for the first
model, blood glucose levels for the second model, and pro-
and anti-inflammatory cytokine profiles for the third and
fourth model respectively. The selected pro-inflammatorycytokines were GM-CSF, IFNγ, IL-1a, IL-1b, IL-6, MCP1,
TNF-α and IL-12p70 and the anti-inflammatory cytokines
were IL-4, IL-10 and IL-13.
In training the model, instead of one week, we considered
gene expression values from two different weeks. This in-
creased the range for independent variable. As a result of
this increased variability our model could capture wider
range of unknown data set for prediction and thus would
decrease its chances for failure. We trained all our models
with early time point gene-expression values as the inde-
pendent variable. We chose gene-expression values from
week 3 and week 6 (we selected genes common to both the
weeks from the master list). In tissues, where this protocol
did not work (i.e., where the model training failed), we
combined those two weeks (week 3 and week 9) and took
the expression profile of the union list as the independent
variable. The disadvantage with the latter protocol was that
Table 2 Model summarizations for both skeletal and adipose SA tissue




Skeletal Body weight 150 HFHSD, KAL-20, KAL-75 Week 3 and week 6 Week 15
Blood glucose 168 HFHSD, KAL-20, KAL-75 Week 3 and week 6 Week 12
Pro-inflammatory cytokines 160 HFHSD, KAL-20, KAL-75 Week 3 and week 6 Week 9 and week 12
Anti-inflammatory cytokines 182 HFHSD, KAL-20, KAL-75 Week 3 and week 6 Week 9 and week 12
Adipose SA Body weight 147 HFHSD, KAL-20, KAL-75 Week 3 or week 6 Week 15
Blood glucose 133 HFHSD, KAL-20, KAL-75 Week 3 or week 6 Week 12
Pro-inflammatory cytokines 144 HFHSD, KAL-20, KAL-75 Week 3 or week 6 Week 9 and week 12
Anti-inflammatory cytokines 186 HFHSD, KAL-20, KAL-75 Week 3 or week 6 Week 9 and week 12
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master list) and so their expression for the other week was
kept blank in the model, which made the model weak.
Nevertheless, we generated a model with the union list that
runs when the intersection protocol fails.Table 3 Test results for KAL-5 and comparison of results with
the model in terms of prediction
Body response parameter Input time (gene expression) Out
Pro- inflammatory cytokine Week 3 Wee
Week 6 Wee
Anti- inflammatory cytokine Week 3 Wee
Week 6 Wee
Body weight Week 3 Wee
Week 6 Wee
Blood glucose Week 3 Wee
Week 6 WeeFor the dependent variable, as mentioned earlier, we
chose different body parameter. The selections of the
critical weeks for each body parameter used in different
models were decided from the experimental data. The
critical week is the time point where the respective bodythe actual experimental results to check the precision of
put time (body parameter) Observed Predicted
















k 9 IL4 41 52.2
IL10 63 68.3
IL13 66 71.3
k 12 IL4 55 54
IL10 78 67.5
IL13 87 66.4
k 15 – 31.4 30.6
k 15 31.4 32.12
k 12 – 160 158.05
k 12 160 158.24










Experimentally observed body weight of the mice




KAL A 30.89 +/− 28.5 29.2 +
KAL B 32.02 - 30.8 37.3 -








glucose level of the
mice
Experimentally observed blood glucose level of
the mice (converted in the range to match the
reference body weight range)
Effectiveness
(Actual)
KAL A 166.33 - 165 180.15 -
KAL B 166.17 - 165 180.15 -
KAL C 164 - 161 174.35 -
Second column has predicted values form the model and the fourth column is the observed values of the model. ‘+’ means the formulation works and ‘-’ means it does
not work and ‘+/−’ means may or may not work.
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point the difference between the body parameter of the
HFHSD mice and ND mice becomes constant. The crit-
ical week for body weight was found to be week 15 and
that for blood glucose was week 12 (see Figure 1(c)-(d)).
For the cytokines (anti and pro-inflammatory) we observed
the critical week to be week 9 (data not shown). However,
we were unable to develop a good model using data only
from week 9. Therefore, the results of week 9 and week 12
were combined and this approach worked well for both
anti- and pro-inflammatory cytokines. Thus for the first
model we chose the body weight of week 15 as the
dependent variable. For second model, we used blood glu-
cose levels (week 12). For third model we used anti-
inflammatory cytokines (week 9 and week 12) and for the
fourth model we used pro-inflammatory cytokines (week 9












NF_1 31.76 +/− 36.7 3
NF_2 32.89 - 38.88333 3
NF_3 33.1 - 37.63333 3
NF_4 31.75 +/− 39.3 3
NF_5 31.48 +/− 41.43333 3
NF_6 31.21 +/− 41 3
NF_7 31.94 +/− 39.98333 3
NF_8 31.07 +/− 36.95 3
NF_9 30.57 +/− 36.68333 3
NF_10 31.24 +/− 34.86667 3
Second column has predicted values form the model and the fourth column is the obs
not work and ‘+/−’ means may or may not work.The model was constructed for each tissue and the re-
sults are summarized in Table 1. It was observed that
models satisfactorily worked only for the SA white adi-
pose tissue and skeletal muscle. The R2-Q2 value for
Skeletal and adipose tissue is given in Figures 2 and 3.
Therefore, we focused on these two tissues and gener-
ated eight models (four models for each tissues corre-
sponding to four physiological parameters), the models
are given in details in Additional file 3. The models con-
sist of finite number of genes, selected based on the VIP
cutoff (see Table 2). Among these two tissues, skeletal
muscle yielded better results as it worked for the set of
genes that were commonly perturbed at both week 3
and week 6. For the adipose tissue on the other hand,
we had to use a combined list of genes from both time
points (union set) as a result of which the independent
variable data set also included genes that were perturbedn formulations
xperimentally observed body weight of the mice














erved values of the model. ‘+’ means the formulation works and ‘-’ means it does









Experimentally observed blood glucose level of the
mice (converted in the range to match the
reference body weight range)
Effectiveness
(Actual)
NF_1 150.087 +/− 153.8333 155.068 +/−
NF_2 155.671 - 168 169.48 -
NF_3 161.86 - 159.5 160.83 -
NF_4 151.751 +/− 152.6667 153.88 +/−
NF_5 160.533 - 167.3333 168.8 -
NF_6 160.029 - 175.3333 176.93 -
NF_7 158.374 - 166.6667 168.12 -
NF_8 160.225 - 155.8333 157.1 -
NF_9 166.757 - 153.1667 154.4 +/−
NF_10 154.106 +/− 150.1667 151.34 +/−
Second column has predicted values form the model and the fourth column is the observed values of the model. ‘+’ means the formulation works and ‘-’ means it does
not work and ‘+/−’ means may or may not work.
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model yield weak predictions. Consequently, we focused
only on the skeletal muscle as the most appropriate tis-
sue for deriving the predictive models of interest.
For model training, we used experimental data consisted
of groups from ND, HFHSD, KAL-20 and KAL-75. Thus
for model testing we could use unknown data of KAL-5
group. The gene-expressions of KAL-5 for week 3 and 6
were used to predict the body weight for week 15, blood
glucose level of week 12 and cytokines (anti-inflammatory
& pro-inflammatory) for week 9 and week 12. In the new
model, we put the gene-expression of the selected genes
under their respective gene names in the X matrix (for the
independent set) and kept the parameter corresponding to
that row empty in the Y matrix (for the dependent set). If
any gene is not present in the new set due to noise filtra-
tion, we kept the spot empty in the X matrix. Once the
model is run we obtained the R2 and Q2 values explaining
the goodness and predictive ability of our model. We com-
pared the predicted values with the experimental value and
the results are given in Table 3. It was observed that body
weight and blood glucose level were better models in terms
of consistency and thus can be used to test biological for-
mulations against obesity and diabetes.
Deriving mathematical scheme for evaluating biological
formulation for obesity and diabetes
The model is ready to predict late time point body parame-
ters, like body weight and blood glucose level, from early
gene expression values obtained from new experiments.
We could check the predictive ability of the models by
comparing the predicted values with the experimentally
obtained results. For comparison, the unknown experi-
mental data need to be normalized with the reference data
(the data used to build the model). For this normalization,
we took the body parameters of the ND and HFHSD miceas the minimum and maximum values of the experimental
range and converted them to the range of the reference ex-
periment. Since this is a linear shift in scale and range, we
used the Celsius-Fahrenheit conversion concept. Let the
body weight of the ND mice of the reference experiment
be x1 gram and HFHSD mice be x2 gram. Let the body
weight of the ND mice of the new experiment be y1 gram
and HFHSD be y2 gram. Since there is a linear relation be-
tween the ND of the model reference with the new experi-
ment (x1, y1), and HFHSD of the model reference with the
new experiment (x2, y2), so these two points will pass
through a line. Let the equation of the line be y =mx + c,
where m is the slope of the line and c is the intercept of
the line. To get the equation we need to find the unknown
parameter m and c. For this we substituted (x, y) from the
equation of the line with (x1, y1) and (x2, y2) and got
y1 ¼ m x1 þ c ð1Þ
y2 ¼ mx2 þ c ð2Þ
Solving equation (1) and equation (2) we obtained m
and c which we was used to convert the values of the
new experiment to the referred experiment. These con-
verted predicted values were then compared with the ex-
perimental observations.
Moreover, to make the model useful in terms of evaluating
biological formulations for obesity and diabetes, we defined
reference ranges for the body parameters distinguishing nor-
mal mice from obese or diabetic mice. We divided the mice
into 3 groups depending on body parameter value. In our
reference experiment, the body weight of the ND mice was
27.5 gram and the body weight of the HFHSD mice was 38
gram. So, the first group consisted of mice considered as
normal body weight ranges between 27.5 gram to 30.125
gram (25% away from ND and 75% from HFHSD). Second
group consisted of mice with body weight between 30.125
Figure 4 The biological classification for the selected genes used in the models. (a)–(d) The genes selected from the models for the adipose
tissue (anti and pro-inflammatory cytokines, blood glucose and body weight). (e) – (h) the genes selected from the models for the skeletal tissue
(anti and pro-inflammatory cytokines, blood glucose and body weight). Here, the abbreviations means: N. Metabolic process- Nucleobase, Nucleoside,
Nucleotide and Nucleic Acid Metabolic Process; C.S.R.L- Cell Surface Receptor Linked; E M C A- establishment or maintenance of chromatin architecture.
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Figure 5 Functional PPI network for skeletal tissue. (a) The PPI network with different coloured nodes (showing their influence over different
physiological parameters) connected through their interactors extracted from STRING data base. Nodes uniquely related to a particular physiological
parameter are: Red nodes—related to body weight, green nodes—related to blood glucose, blue nodes—related to anti- inflammatory cytokines and reddish
yellow nodes— related to pro-inflammatory cytokines. Magenta coloured nodes are for genes influencing more than one physiological parameter. (b) The
power law distribution of the network showing its “scale-free” property.
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Figure 6 Functional PPI network for adipose SA tissue. (a) The PPI network with different coloured nodes (showing their influence over different
physiological parameters) connected through their interactors extracted from STRING data base. Colour codes are same as in Figure 5. (b) The power law
distribution of the network showing its “scale-free” property.
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mice in this group showed sign of possible obesity. For
body weight more than 32.75 gram, the mice were said tobe obese and we put them in third group. Similarly we pro-
posed ranges for the blood glucose level. In the reference
experiment, ND mice had blood glucose level equal to
Table 7 The parameters related with node connectivity for the sub-networks extracted from the skeletal network given
in Figure 5(a)












Signal transduction, cell communication
and cell motion
166 0.28 0.316 4.46 0.062 2.083
Translation and N. Metabolic processes 526 0.516 0.507 5.038 0.05 3.967
Apoptosis 115 0.39 0.443 4.4 0.04 2.081
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cose level lies between 141 mg/dl and 148.25 mg/dl, we re-
ferred it as normal. Second group consisted of mice with
slight increase in blood glucose level (148.25 mg/dl to
155.5 mg/dl). For blood glucose level more than 155.5 mg/dl,
the mice were said to be diabetic and we put them in
the third group. If the biological formulation works and
keeps the body parameters within the normal range then
we denote it by ‘+’. If the formulation partially works on
the body parameters and the values are in the second
group (described above), we denote it by ‘+/−’. Finally, in
spite of exposing to the formulation, if the body parameter
shows obese and or diabetic state then we denote it by ‘−’.
Model predictions on the effectiveness of unknown
formulations for obesity and diabetes
We performed a blind experiment where the goal was to
predict outcomes of HFHSD mice treated with three dif-
ferent ethno-botanical formulations of unknown func-
tion. These three blind formulations, named as KAL-A,
KAL-B, and KAL-C, were obtained from the manufac-
turer of KAL-1 and the data, in terms of the physio-
logical parameters, were generated in a similar manner.
Gene-expression data were generated from the skeletal
muscle from different groups at weeks 3 and 6. We also
obtained body parameters (body weight and blood glu-
cose level) for later time point. The body weight and
blood glucose of ND mice were 28 grams (week 15) and
138 mg/dl (week 12) respectively, and the body weight and
blood glucose of HFHSD mice were 31 grams (week 15)
and 158 mg/dl (week 12), respectively. Thus the conversion
parameters (m and c) for the body weight and blood glu-
cose level for this new experiment were (3.5, −70.5) and
(1.45, −59.1), respectively. We used these two parameters
to compare our prediction with the observed results. The
model predictions for the new experiment (KAL-A, KAL-B
and KAL-C) are given in Table 4. We observed that our
predictions regarding the effectiveness of the biological for-
mulations match with the experimental observations, ex-
cept in case of border line predictions.
To check the robustness of the proposed models, we
further tested them with ten more blind formulations
(NF_1, NF_2, NF_3, NF_4, NF_5, NF_6, NF_7, NF_8,
NF_9 and NF_10). The body weight and blood glucoseof ND mice were 29 grams and 140 mg/dl respectively.
The body weight and blood glucose of HFHSD mice
were 34.5 grams and 169.5 mg/dl, respectively. Thus the
conversion parameters (m and c) for the body weight
and blood glucose level for this new experiment were
(1.0972, −8.0273) and (1.017, −1.38) respectively. The
model prediction for the new experiment with ten blind
formulations is given in Tables 5 and 6. We observed
that most of the predictions were correct except for
some border line cases. Thus, the trained model showed
a good first approximation on evaluating the effective-
ness of the formulations against obesity and diabetes. Al-
though with the failure in some border line cases,
implied the need for further training of the model.
Nevertheless, we have a model (trained and tested) that
can be used as first-line screen to test the activities of
formulations (including pharmacological compounds).
Finding relation between biological processes associated
with the signature genes and the body phenotype
The genes present in the proposed models (selected by
the VIP score) could possibly regulate or influence the re-
lated physiological parameters. To find the functionality
associated with these genes we looked for functional en-
richment of the data. We analyzed the protein functional
clusters using the online tool called PANTHER (Protein
Analysis through Evolutionary Relationships; http://www.
pantherdb.org) Classification System. PANTHER is a
ontology tool where proteins are classified into families
and subfamilies of shared function, which are further
assigned to specific ontology terms in the two main
categories- biological process and molecular function [16].
Here, we have eight set of genes (each set for each model)
for skeletal and adipose SA tissue. Each of these sets are re-
lated (through model) with one of the parameter- (1) body
weight, (2) blood glucose, (3) anti-inflammatory cytokines
and (4) pro-inflammatory cytokines. In each group, we
identified the key processes that were associated with these
proteins, using the Panther HMM algorithm based on
homology and trained on known proteins, see Figure 4. To
identify these key processes, we first selected the processes
based on significant p values (<1E-01) and the resulting list
was further screened by selecting only those processes that
involved more than 2 proteins. The list of biological
Figure 7 Functionally defined modules extracted from the skeletal network given in Figure 5(a). (a)-(b) Signal transduction, cell communication
and cell motion; (c)-(d) Translation and N. Metabolic processes; and (e)-(f) Apoptosis. (a), (c) and (e) are the sub-networks and (b), (d) and (f) are
the corresponding node-degree distribution, using which we obtained the hub proteins.
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http://www.biomedcentral.com/1752-0509/8/104processes obtained for each set of signature gene is given in
Additional file 4.
We observed that there were some processes significantly
(with p values <1E-01) present in both tissues (adipose and
skeletal) and influence the same physiological parameter.
For example, cell communication (with p-value 4.88E-03 in
adipose and 1.92E-02 in skeletal), signal transduction (with
p-value 4.27E-03 in adipose and 3.35E-02 in skeletal) and
vesicle mediated transport (with p-value 2.22E-02 in adi-
pose SA and 3.91E-02 in skeletal) were the key processes
involve in both tissues and influence pro-inflammatory
cytokine. So, there are lot of initial cell signalling events oc-
curred that influence later time points pro-inflammatory
cytokine profiles and this happens in both tissues. We also
observed processes like proteolysis and cell motion that
were significantly present in both the tissues. Former re-
lated to anti-inflammatory cytokines and later influences
body weight. For blood glucose we observed translation
and nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process significantly present in both the tissues.
There was no process commonly involved in all physio-
logical changes for both the tissues, but there were processes
uniquely present in each tissue and were involved in a par-
ticular physiological change. For example, genes involved in
phospholipid metabolic process (9.38E-02) were present in
adipose tissue influencing the body weight. This process was
involved in the formation of lipid bilayers. Two more pro-
cesses significantly present in adipose tissue were cellular
defence response (9.58E-03) and regulation of apoptosis
(9.18E-02) and they influenced anti-inflammatory cytokine.
We also observed immune response (5.83E-02) in adipose
tissue which influences the pro-inflammatory cytokine pro-
files. In skeletal tissues the key process includes transport
(3.21E-02) like intra cellular protein transport and apoptosis
(8.07E-02).
Extracting biological network from the signature genes
and identification of hub proteins
We obtained relations between different biological processes
and body parameters like body weights, blood glucose levels
and cytokine profiles. These processes were obtained from
the genes present in the early time point and the body pa-
rameters were taken from later time point. This kind of link-
age can trace disease development and progression, but for
that we need to understand how the perturbations in a
protein affect other proteins and how these changes are
reflected on the body parameter. For this, we need to con-
struct the protein-protein interaction (PPI) functional net-
work. We used STRING (Search Tool for the retrieval of
Interacting genes/ proteins) database, which detect physical
and functional associations of the proteins and shows con-
nection between two proteins if they are co-regulated, co-
expressed or present in the same protein complex. We
downloaded protein-protein interaction from STRING dataset and used only those interactions that were obtained dir-
ectly from experiment. (http://string-db.org/).
We built two PPI networks for the two tissues- skeletal
and adipose, by combining the signature genes from all
the models (for each tissue). The nodes (present in our
list) were represented with different colours and were con-
nected through their interactors extracted from STRING
database, see Figures 5(a) and 6(a). In our constructed net-
work we go for different statistical analysis. The first one
is the degree-node distribution. The degree distribution is
an important statistical property to measure the global
structure of large networks [17]. The degree distribution,
P(k), describes the probability that a node has degree k. A
scale-free networks (important property relevant to PPI
network [14]) have a power-law degree distribution P(k) ∼
ck−γ , where γ is a positive number [17-19]. Our network
also showed power law distribution (see Figures 5(b)-6(b))
and hence it possesses “scale free” property.
In both the networks we obtained different enriched
sub-networks based on the functional classification with
low p-value (<10−1) obtained using PANTHER. To test
the statistical significance of the sub-networks in terms of
connectivity, we calculated the parameters like network
centralization, network density and network heterogeneity
for each of the proposed sub networks. These parame-
ters are related with node connectivity, for example,
centralization is an index of the connectivity distribu-
tion and network heterogeneity are based on the vari-
ance of the connectivity [20]. Moreover in each of these
sub-networks (or functional modules) we identified
some hub proteins. Here we focused on intra-modular
hub proteins which has high clustering coefficient [21].
Functional modules in skeletal tissue
There were mainly three functionally sub-networks ob-
served in this network. The statistics for each sub-network
is given in Table 7. First one was “Signal transduction, cell
communication and cell motion” which contains proteins
that play a central role in signalling pathway (see Figure 7
(a)). From the node-degree distribution, we obtained the
average neighbourhood for each node and took eight nodes
(top 5%, see Figure 7(b)) as hub-nodes, see Table 8. The
second sub-network was “Translation and nucleobase, nu-
cleoside, nucleotide and nucleic acid metabolic processes”
containing proteins that play a central role in metabolic
pathway (see Figure 7(c)). From the node-degree distribu-
tion, we obtained ten nodes (top 2%, see Figure 7(d)) as
hub-nodes, see Table 8. The third sub-network plays a cen-
tral role in apoptosis (see Figure 7(e)) and we obtained six
nodes (top 5%, see Figure 7(f)) as hub-nodes, see Table 8.
Functional modules in adipose tissue
Here also three functionally sub-networks were observed
and the statistics for each sub-network is given in Table 9.
Table 8 The list of hub proteins obtained in different modules in the skeletal network given in Figure 5(a)
Biological sub-network Number of hub nodes Name of the proteins Number of nodes connected with
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http://www.biomedcentral.com/1752-0509/8/104First one was “Signal transduction, cell communication and
cell motion” which contained proteins from signalling path-
way (see Figure 8(a)). From the node-degree distribution,
we obtained five nodes (2%, see Figure 8(b)) as hub-nodes,
see Table 10. The second sub-network was “Translation, N
Metabolic Process, Phospholipid metabolic Process” that
play important part in different metabolic process (see
Figure 8(c)). Here we obtained eight nodes (top 2%, Figure 8
(d)) as hub-nodes, see Table 10. The third sub-network
consisted of proteins that were part of immune response
pathway (see Figure 8(e)). We obtained three nodes
(top 3%, see Figure 8(f)) as hub-nodes, see Table 10.Table 9 The parameters related with node connectivity for th
given in Figure 6(a)









Translation, N. Metabolic process,
Phospho-lipid Metabolic process
459 0.613 0.4
Immune response 90 0.023 0.5Discussion
Present study was devoted in finding gene signatures for
obesity and diabetes systemic inflammation. Using the par-
tial least square discriminant analysis (PLS-DA) method,
we identified early gene/molecular signatures that pre-
dicted future values of physiological parameters like body
weight, blood glucose levels and cytokine profiles. The
models worked better for Skeletal & Adipose SA tissues in
predicting body weight and blood glucose (two important
physiological parameters for obesity and diabetes). To test
the effectiveness of the biological formulations against









76 3.176 0.008 5.608
99 3.542 0.008 4.448
04 2.111 0.024 2.398
Figure 8 Functionally defined modules extracted from the adipose SA network given in Figure 6(a). (a)-(b) Signal transduction, cell
communication and cell motion; (c)-(d) Translation, N. Metabolic processes and Phospho-lipid Metabolic Process; and (e)-(f) Immune response.
(a), (c) and (e) are the sub-networks and (b), (d) and (f) are the corresponding node-degree distribution, using which we obtained the hub proteins.
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Table 10 The list of hub proteins obtained in different modules in adipose SA network given in Figure 6(a)
Biological sub-network Number of hub nodes Name of the proteins Number of nodes
connected with













Immune response 3 Canx 46
Hsp90Aa1 13
Mcl1 12
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http://www.biomedcentral.com/1752-0509/8/104weights and blood glucose levels. It was observed that the
models, with these cut offs, work well in evaluating the for-
mulations, except in some border cases for which the
model needed further training. Thus, we have models that
predict future body weight and blood glucose level from
early gene expression values, which could be a good start-
ing platform for screening experiment.
We also studied the functionality of the obtained sig-
nature genes for each model. We observed that some of
the biological processes were common in both the tis-
sues and influenced more than one physiological param-
eter. There were biological processes uniquely present in
a tissue and were associated with a particular physio-
logical parameter. After identifying the significant bio-
logical processes (p-value < 1E-01) for both skeletal and
adipose SA, we used them to build functional modules
for both the tissues (using STRING database). Studying
those modules carefully we obtained hub proteins with
some of them has the potential to be an early marker for
obesity and diabetes.
For skeletal tissues we obtained 15 unique hub proteins
from different modules, influencing different future physio-
logical parameters and for adipose tissue we obtained 16
unique hub proteins, see Additional file 5 (proteins with
their functional modules and the physiological parameters).
We observed heat shock proteins Hspbp1 in skeletal tis-
sue (signaling and metabolic module) influencing future
anti-inflammatory cytokine profiles. Heat shock proteins
(HSPs) function at the cellular level to protect cells against
many chronically and acutely stressful conditions [22].
Thus response to early stress due to HFHSD was observedin the mice. Another key protein identified in apoptosis
pathway and influence future blood glucose level was Akt1.
We know that Akt1 phosphorylation is essential for insulin
signaling in skeletal muscle [23]. Our study identified Akt1
as a key signature gene in skeletal tissue for predicting fu-
ture blood glucose level. Another key signature gene in
skeletal tissue was Ybx1 which predicts future anti-
inflammatory cytokine profiles. This is an interesting result
because Ybx1 is an important molecule associated with in-
flammatory stress [24] and here its early expression in the
skeletal tissue was used to predict the future outcome in
terms of inflammation. We have also identified some key
ribosomal proteins (Rpl17, Rpl19, and Rp17) as signature
molecules for predicting future inflammatory stress.
In adipose SA we found key proteins from signaling
pathway, metabolic pathway and immune response. Im-
mune response and metabolic regulation are highly inte-
grated function and any kind of dysfunction may lead to a
cluster of chronic metabolic disorders, particularly obesity,
type-II diabetes and cardiovascular disease [25]. In immune
response module we found a highly connected molecule
Calnexin which is an important molecule found in obesity
[26]. We identified a key signature protein Flnc (highly
connected in the signaling module) associated with future
inflammation stress. This protein is known to associate
with obesity and diabetes [27]. Ctnnb1 is another impor-
tant protein identified in the signaling module, known as
an important players in Wnt and p53 signalling pathways,
which would provide a putative link between Type-II dia-
betes and certain types of cancer [28]. This identified key
signature is observed to influence the future body weight.
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We proposed sets of gene/molecular signatures for predict-
ing different physiological parameters associated with obes-
ity and diabetes. This could be used as a first step in
evaluating effectiveness of the formulations against obesity
and diabetes. Our analysis revealed that some of the identi-
fied key signature genes have the potential to become early
biomarker for obesity and diabetes, admittedly however, it
necessitates further validation.
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